< 1 minute read
Oct. 6, 2021

BAY-8400: An Oral Selective DNA-PK Kinase Inhibitor

BAY-8400

oral selective DNA-PK kinase inhibitor synergy with radiotherapy in model from library screen Journal of Medicinal Chemistry Bayer AG, Berlin, Germany

twitterlinkedinprintemail